Serum anti‐endothelial cell antibodies in patients with age‐related macular degeneration treated with intravitreal bevacizumab

Kubicka‐Trząska, Agnieszka; Wilańska, Joanna; Romanowska–Dixon, Bożena; Sanak, Marek

doi:10.1111/aos.13033

Cited by 8 publications

(9 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Kubicka‐Trzaska et al. ) Also, a variant of the complement factor H (CFH) gene, which causes uncontrolled complement activation, has been linked to AMD. (Nussenblatt et al.…”

Section: Introductionmentioning

confidence: 99%

“…(Heckenlively et al 1999) Decrease in serum ARA levels was reported after intravitreal antivascular endothelial growth factor (VEGF) therapy in AMD. (Kubicka-Trzaska et al 2016) Also, a variant of the complement factor H (CFH) gene, which causes uncontrolled complement activation, has been linked to AMD. (Nussenblatt et al 2013) The presence of ARAs in aqueous humour and serum has been observed in patients with glaucoma and in neurodegenerative damage of the optic nerve.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age‐related macular degeneration, glaucoma and cataract

Berge

Fazil

Born

et al. 2018

Acta Ophthalmologica

101

View full text Add to dashboard Cite

Purpose To analyse intraocular cytokine levels and prevalence of intraocular antiretinal antibodies (ARAs) in patients with retinitis pigmentosa (RP), age‐related macular degeneration (AMD), glaucoma and cataract, and correlate the results to clinical manifestations. Methods We collected intraocular fluid samples from patients with RP (n = 25), AMD (n = 12), glaucoma (n = 28) and cataract (n = 22), and serum samples paired with the intraocular fluids from patients with RP (N = 7) and cataract (n = 10). Interleukin (IL)‐1β, IL‐1ra, IL‐2, IL‐6, IL‐6rα, IL‐7, IL‐8, IL‐10, IL‐17A, IL‐23, thymus‐ and activation‐regulated chemokine (TARC), monocyte chemoattractant protein‐1 (MCP‐1), tumour necrosis factor‐alpha (TNF‐α), placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) were measured using a multiplex assay. Antiretinal antibodies (ARA) detection was performed by indirect immunofluorescence. Results Increasing age was associated with increasing levels of IL‐6, IL‐8, TNF‐α and VEGF. All patient groups exhibited distinct profiles of intraocular cytokines. Intraocular levels of IL‐8 were highest in patients with AMD and glaucoma. Cataract patients exhibited high intraocular levels of IL‐23. Intraocular levels of IL‐2, IL‐6, MCP‐1 and PlGF in RP patients exceeded the levels of serum, indicating intraocular production. Intraocular ARAs were found in only one patient with AMD. Conclusion Increased levels of inflammatory cytokines in intraocular fluid of patients with originally noninflammatory ocular diseases show that intraocular inflammation is involved in their pathogenesis of these entities. Moreover, we show that increasing age is associated with increasing levels of intraocular cytokines and conclude that future studies on intraocular mediators should be corrected for age of patients.

show abstract

“…(Kubicka‐Trzaska et al. ) Also, a variant of the complement factor H (CFH) gene, which causes uncontrolled complement activation, has been linked to AMD. (Nussenblatt et al.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age‐related macular degeneration, glaucoma and cataract

Berge

Fazil

Born

et al. 2018

Acta Ophthalmologica

101

View full text Add to dashboard Cite

show abstract

“…[13] Recent investigations have demonstrated that the concentration of AECA decreases in patients receiving bevacizumab. [14] Moreover, high expression of VEGF was reported in patients with vasculitis and in children with acute-phase IgAV. [15,16] Some reports suggest that bevacizumab administration is unlikely to lead to the development of IgAVN.…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab-induced immunoglobulin A vasculitis with nephritis

Endo

Negishi²,

Hirayama³

et al. 2019

Medicine

View full text Add to dashboard Cite

Rationale:Bevacizumab—an inhibitor of vascular endothelial growth factor—is effective against various advanced cancers. However, it is associated with the development of hypertension and high-grade proteinuria during thrombotic microangiopathy of the kidney. In addition, there are several reports of immunoglobulin A deposition in the glomeruli, but the etiology is unclear.Patient concerns:A 67-year-old Japanese man with metastatic rectal cancer underwent low anterior rectal resection, followed by treatment with bevacizumab and SOX (S-1 plus oxaliplatin). Six months later, the patient developed hematuria, nephrotic syndrome, and purpura.Diagnoses:Renal biopsy revealed endocapillary proliferative glomerulonephritis. Immunofluorescence analyses showed granular mesangial deposition of galactose-deficient immunoglobulin A1. Skin biopsy revealed leukocytoclastic vasculitis.Interventions:We ceased bevacizumab treatment, while continuing the remaining chemotherapy regimen, as we suspected bevacizumab-induced nephropathy.Outcomes:Proteinuria and purpura improved immediately after cessation of bevacizumab. We identified this as a case of bevacizumab-induced immunoglobulin A vasculitis with nephritis.Lessons:To our knowledge, this is the first case of bevacizumab-related immunoglobulin A vasculitis with nephritis, as evidenced by galactose-deficient immunoglobulin A1. When a patient's urine tests are abnormal during bevacizumab treatment, clinicians should consider not only thrombotic microangiopathy but also vasculitis.

show abstract

“…Interestingly, organ-specific autoreactivity (ARA) appears to be suppressed in both active and latent TB; however, the local production of ARA in ocular fluid samples was not investigated in this series. The presence of serum autoantibodies, directed against endothelial cells, and their decrease following treatment were reported in age-related macular degeneration (Kubicka-Trzaska et al 2016). Unfortunately, we have no samples of our patients after they completed the treatment.…”

Section: Referencesmentioning

confidence: 91%

Antinuclear and antiretinal antibodies in uveitis associated with active and latent tuberculosis

Nora

Berge

Rothová

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

Serum anti‐endothelial cell antibodies in patients with age‐related macular degeneration treated with intravitreal bevacizumab

Abstract: There is growing evidence that AMD is an immune-mediated disease, and thus it cannot be excluded that AECA may be involved in its pathogenesis and progression. We also speculate that AECA develop in response to retinal damage and anti-VEGF therapy.

Cited by 8 publications

References 28 publications

Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age‐related macular degeneration, glaucoma and cataract

Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age‐related macular degeneration, glaucoma and cataract

Bevacizumab-induced immunoglobulin A vasculitis with nephritis

Antinuclear and antiretinal antibodies in uveitis associated with active and latent tuberculosis

Contact Info

Product

Resources

About